SGO Recap & ASK the DOC - April 8, 2015 Chat

Twenty-nine participants joined us to discuss the latest research news from the SGO Annual Meeting held in March. Contributing to our discussion were Dr. Don S. Dizon and Dr. Ann Becker-Schutte, two of #gyncsm's healthcare moderators, as well as Dr. William Winter (NED the Band), Dr. Shannon Westin, Dr. Matthew Katz, Dr. Stephanie Blank and Lisa M Guzzardi, RN.

You may find the transcript here and analytics here. 

Some of the questions and responses during the chat are below:

T1: Pls comment on the study at SGO you found of most note. Was it OC FANG vaccine/ GOG 213 studies/ other?

T1: Tho study was smalll, FANG vaccine for #ovariancancer is very exciting #immunotherapy has promise - esp in maintanence setting #gyncsm
— Shannon Westin (@ShannonWestin) April 9, 2015

T1 @btrfly12 #gyncsm fang vaccine was for consolidation, i.e. after patients had had a complete response to front line chemotherapy
— Stephanie Blank (@StephanieVBlank) April 9, 2015

T1: GOG213:Avastin 4 platinum-sens #ovariancancer had similar results 2 prior studies - PFS benefit, Near OS benefit - but not quite #gyncsm
— Shannon Westin (@ShannonWestin) April 9, 2015

#gyncsm I was encouraged by the biomarkers found from the ARIEL2 study #sgo2015
— Stephanie Blank (@StephanieVBlank) April 9, 2015

Impact of @theNCI Comprehensive Cancer Centers on #OvarianCancer Treatment and Survival. #gyncsm http://t.co/6b20oHx8tH
— Lisa M Guzzardi, RN (@LguzzardiM) April 9, 2015

T2: Which ovarian cancer research results are most exciting to you? Immunotherapy? Bevacizumab? Parp inhibitors?

T2: Certainly the PARP inhibitor data are very consistent for #ovariancancer - nice results for #BRCA pts as well as select non-BRCA #gyncsm
— Shannon Westin (@ShannonWestin) April 9, 2015

T3: Pls discuss the implications of Dr Joura’s HPV study on cervical cancer & the Circulating Tumor Cells / Bevacizumab study. 

T3: The ability to monitor response to therapy with a blood marker ie "liquid biopsy" is a huge innovation #gyncsm
— Shannon Westin (@ShannonWestin) April 9, 2015

@gyncsm: studies re: BRCA 1) majority of BRCA carriers don’t have family hx 2) most ovarian cancer patients don’t know BRCA status.  

T4: How will these BRCA studies impact surveillance, ed, treatment?

#SGO2015 Ian Jacobs. Most BRCA mutation carriers don't have a family hx of cancer pic.twitter.com/M0Sp798Tqw
— Jurgen Piek (@JurgenPiek) March 29, 2015

@btrfly12 most gyn cancer centers auto referring for genetic testing after ovca dx. #gyncsm
— Don S Dizon (@drdonsdizon) April 9, 2015

T5: Now we open the chat for questions from our participants re: news they heard from the SGO mtg.

• T5: any studies reveal benefit regarding endo ca recvng maint chemo Stage IIIc2 currently NED     A:Nothing yet - we need more maintenance studies for gynecologic cancers
• T5: Question - any radiation oncology news from SGO?   A:there was very little major research on #radonc this year
• T5: Does current genetic testing for #OC include mutations like TP53,RAD51D,etc ? Or just BRCA?Is this imp ?   A:#gyncsm panel testing test for many more mutations. should speak w genetic counselor. some is imp, some for future #sgo2015   
• T5:Thoughts on how should patients/loved ones approach new study findings?   A:Open mindedness and always validate its credibility too

Our next chat will be at 9pm EST on May 13, 2015 . We will be joined by Kelly Mellott (@HelomicsCancer) as we discuss Personalized Medicine Advances for GYN Cancers. 

Patients & caregivers are invited to continue our discussion on the Smart Patients platform at https://www.smartpatients.com/partners/gyncsm.


Dee
Co-moderator #gyncsm chat


Resources shared during the chat: 

Highlights from the SGO Mtg
http://www.cancernetwork.com/conference-report/top-highlights-2015-sgo-annual-meeting

@SGO_org paper on end-points in Clinical trials
https://t.co/gNiU6SUICP

Incidental power morcellation of malignancy: a retrospective cohort study. - PubMed - NCBI 
http://t.co/pJOVG9XCfr

Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer 
http://jama.jamanetwork.com/article.aspx?articleid=2214084#.VSXXv-chiQ8.twitter

Advanced Cervical Cancer and Circulating Tumor Cells treated with Bevacizumab

http://www.targetedonc.com/conference/sgo-2015/Patients-with-Advanced-Cervical-Cancer-and-Circulating-Tumor-Cells-Treated-With-Bevacizumab-Show-Improved-OS

Postmenopausal HRT & use of estradiol plus levonorgestrel IUD is assoc with increased risk of fallopian tube cancer
http://t.co/ppFIu9EDou

Additional Resources:

SGO Highlights:

OCNA:
http://www.ovariancancer.org/wp-content/uploads/2014/04/2015-SGO-Research-Roundup.pdf

Women of Teal Blog:
http://womenofteal.blogspot.com/2015/03/sgo-from-distance.html and http://womenofteal.blogspot.com/2015/03/sgo-from-distance-part-2.html

AVASTIN GOG 213

OncLive “overall survival (OS) of nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer, according to results from the phase III GOG0213: “

http://www.onclive.com/conference-coverage/sgo-2015/Bevacizumab-Regimen-Extends-Survival-in-Phase-III-Ovarian-Cancer-Trial

http://www.targetedonc.com/conference/sgo-2015/Bevacizumab-Regimen-Hits-New-OS-Milestone-in-Ovarian-Cancer

mixed results GOG 213 http://www.medpagetoday.com/MeetingCoverage/SGO/50720

http://consumer.healthday.com/cancer-information-5/avastin-news-806/progress-reported-in-battling-advanced-ovarian-cancer-697822.html

Surgeon vs CT results of size of tumors left behind.

http://www.medpagetoday.com/MeetingCoverage/SGO/50748

Fosbretabulin /Avastin

OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer

http://investor.oxigene.com/releasedetail.cfm?releaseid=881614

Immunotherapy

http://immuno-oncologynews.com/2015/03/30/immunotherapy-delays-recurrence-of-both-stage-iii-and-iv-ovarian-cancers/

IP chemo advantages

http://www.targetedonc.com/articles/Survival-Advantage-Seen-With-IP-Chemotherapy-for-Ovarian-Cancer

Recommendations for the prevention of ovarian cancer : SGO

http://onlinelibrary.wiley.com/doi/10.1002/cncr.29321/full

Dr Brawleys commentary-http://onlinelibrary.wiley.com/enhanced/doi/10.1002/cncr.29347/

PARP inhibitor - olaparib (Lynparza)

http://www.medpagetoday.com/MeetingCoverage/SGO/50774?xid=nl_mpt_DHE_HZ_2015-04-02&utm_content&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=ST&eun=g794905d0r&userid=794905&email=robyn.kurth%40sgo.org&mu_id=6075589

diagnostic tool- bracaAnalysis

http://www.targetedonc.com/conference/sgo-2015/bracanalysis-cdx-companion-diagnostic-progresses-personalized-ovarian-cancer-treatment

FANG vaccine trial / Immunotherapy

http://immuno-oncologynews.com/2015/03/30/immunotherapy-delays-recurrence-of-both-stage-iii-and-iv-ovarian-cancers/

http://www.medpagetoday.com/MeetingCoverage/SGO/50739

https://sgo.confex.com/sgo/2015/webprogram/Paper4165.html *abstract

Endometrial Cancer -Cediranib
http://www.targetedonc.com/conference/sgo-2015/Cediranib-Monotherapy-Safe-Effective-in-Endometrial-Cancer

April Chat: SGO Annual Meeting Recap and ASK the DOC

This month's #gyncsm chat ( 4/8/15, 9pm EST) will focus on news from the SGO Annual Meeting on Women's Cancer including a segment we call ASK the DOC. 

The SGO's  (Society of Gynecologic Oncology) Annual Meeting on Women's Cancer was held in Chicago on March 27th to the 31st. The SGO " is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers" and they encourage research and provide education for women's cancer care. The agenda included presentations and poster sessions on the prevention and screening of gyn cancers, novel approaches to the management of gyn cancers, translational research, improvements in patient outcomes as well as the implications of global research. 

We will begin our chat on Wednesday by discussing research results reported at this year's annual meeting. Some of the studies include:

FANG vaccine for ovarian cancer 

GOG 213 (a randomized trial comparing carboplatin and paclitaxel with or without bevacizumab in platinum sensitive relapsed ovarian cancer patients.)

Immunotherapy

Parp inhibitors including  Cediranib and Endometrial cancer

An HPV study on cervical cancer & the CTC (Circulating Tumor Cells)  / Bevacizumab (Avastin) study  

BRCA 1 & 2 mutations: One study showed that a  majority of BRCA carriers don’t have family a family history of breast or ovarian cancer while a second study showed that most ovarian cancer patients don’t know their BRCA status. 

Benefits to being treated at a high volume hospital

Join us as we discuss how studies such as these will impact surveillance, education and treatment.

You may read the abstracts from the meeting here. While videos from the meeting including "Meet the Professor" may be found here. Some tweets related to studies reported on at the annual meeting may be found on the blog posts SGO From a Distance and SGO From a Distance Part 2. 

OCNA has provided highlights from the meeting that are of particular interest to ovarian cancer survivors here. Additional highlights provided by Cancer Network (home of the Journal Oncology) may be found here. 

Included in this chat will be our ASK the DOC segment. All chat participants (patients, survivors, caregivers, advocates, etc.) will have the opportunity to ask our docs questions related to the research reported on at the meeting. Maybe there is a research area we had not covered that you are interested in learning more about. ASK the DOC is the perfect time to get your questions answered. 

We are pleased that this month our health care moderators (Dr. Don S. Dizon, Dr. Rick Boulay, Dr. Merry-Jennifer Markham, Dr. Ann Becker-Schutte) will be joined by Dr. William Winter III, a gynecologist oncologist and lead guitarist with NED The Band. Dr. Winter will be tweeting as @NEDthemovie. 

We look forward to you joining us as we talk about the latest research on gynecologic cancers. 


Dee
#gyncsm co-moderator